33rd week of 2011 patent applcation highlights part 33 |
Patent application number | Title | Published |
20110200531 | TREATMENT AND DIAGNOSIS OF CENTRAL NERVOUS SYSTEM DISORDERS - The invention relates to the use of tetramethylpyrazine (TMP) for the treatment of patients at risk for the development of, or diagnosed as having, CNS disorders such as Alzheimer's disease (AD), Parkinson's disease (PD), glaucoma, and Huntington's Disease (HD), as well as traumatic brain injury (TBI). The present invention also relates to the use of retinal imaging to diagnose and monitor efficacy of treatments for such CNS disorders. | 2011-08-18 |
20110200532 | Fluorescent emulsion of indocyanine green - The present invention relates to a formulation of indocyanine green in the form of a nanoemulsion, comprising a continuous aqueous phase and at least one dispersed oily phase, in which the oily phase comprises indocyanine green, at least one amphiphilic lipid and at least one solubilising lipid. | 2011-08-18 |
20110200533 | COMPOUNDS FOR THE DIAGNOSIS OF DISEASES ASSOCIATED WITH VCAM EXPRESSION - The present invention relates to a compound of the following general formula (I): | 2011-08-18 |
20110200534 | T1-T2 Dual Modal MRI Contrast Agents - The present invention relates a T1-T2 dual-modal MRI (magnetic resonance imaging) contrast agent, comprising (a) a first layer consisting of T1 contrast material; (b) a second layer consisting of T2 contrast material; and (c) a separating layer which is present in a space between the first layer and the second layer, and inhibits a reciprocal interference between T1 contrast material and T2 contrast material, and a heat-generating composition and a drug delivery composition having the same. The T1-T2 dual-modal contrast agent of the present invention may generate both T1 and T2 signal and thus observe the signal complementarily, resulting in accurate diagnosis through reduction of misdiagnosis. Further, T1 and T2 MR imaging may be simultaneously obtained by simple operation within the same MR imaging device, enabling to remarkably reduce a diagnosis time and diagnosis cost. In addition, the particle constituting the T1-T2 dual-modal contrast agent of the present invention may be applied to hyperthermia and drug delivery systems. | 2011-08-18 |
20110200535 | DAA-PYRIDINE AS PERIPHERAL BENZODIAZEPINE RECEPTOR LIGAND FOR DIAGNOSTIC IMAGING AND PHARMACEUTICAL TREATMENT - This invention relates to novel compounds suitable for labelling or already labelled by | 2011-08-18 |
20110200536 | CHELATORS, PARAMAGNETIC CHELATES THEREOF AND THEIR USE AS CONTRAST AGENTS IN MAGNETIC RESONANCE IMAGING (MRI) - The present invention relates to chelators, in particular to chelators which are capable of forming complexes, i.e. paramagnetic chelates, with paramagnetic metal ions. The invention also relates to said paramagnetic chelates, said paramagnetic chelates linked to other molecules and their use as contrast agents in magnetic resonance imaging (MRI). | 2011-08-18 |
20110200537 | LASER MARKED DOSAGE FORMS - The present invention relates to a coated dosage form having openings to expose the core material or an intermediate coating layer. The invention also relates to methods for manufacturing such coated dosage forms. | 2011-08-18 |
20110200538 | Alternan Derivatives - The present invention relates to alternan-carboxylic acid esters, to processes for the preparation of alternan-carboxylic acid esters, and to compositions comprising alternan-carboxylic acid esters and to the use of alternan-carboxylic acid esters. The invention relates to alternan-carboxylic acid esters which are emulsifiers. | 2011-08-18 |
20110200539 | Sprayable composition comprising extract of red vine leaves - Disclosed are sprayable compositions containing red vine leaf extract, which can be sprayed onto the skin using suitable spray devices. | 2011-08-18 |
20110200540 | MIXTURES COMPRISING BENZOTRIAZOLES AND MEROCYANINES - The present invention relates to the use of a stabilizing composition comprising
| 2011-08-18 |
20110200541 | RECOMBINANT PREPARATION OF BROMELAIN INHIBITORS AND BROMELAIN INHIBITOR PRECURSOR - The present invention pertains in general to Bromelain and particularly to the active compounds contained in this complex mixture of proteins. The present invention provides recombinant expressed Bromelain inhibitor precursor and Bromelain inhibitors, which are found in Bromelain. It has been found that the recombinant expressed inhibitors have superior effects in terms of treatment of disorders and conditions than Bromelain or its protein fractions from plant extracts. | 2011-08-18 |
20110200542 | SKIN CANCER PREVENTION METHOD AND PRODUCT - The increased use of sunscreens, while limiting damage to the DNA, may promote cancer growth by preventing vitamin D synthesis in the skin. According to the present invention, the beneficial effects of UV radiation are obtained by incorporating vitamin D into the topical composition such as topical sunscreen or topical after-sun composition (lotion or cream). Application of the sunscreen prevents the harmful effects of UV radiation and the included vitamin D is activated by the skin to calcitriol for cancer prevention. Application of the after-sun composition prevents the harmful effects of UV radiation because the included vitamin D is activated by the skin to calcitriol for cancer prevention. Because calcitriol also promotes cellular growth and differentiation, the topical composition with vitamin D may be of benefit for photo aging. | 2011-08-18 |
20110200543 | ANHYDROUS FLUID FILTERING COMPOSITION COMPRISING AN OILY PHASE, A PARTICULAR TRIAZINE FILTER AND AN OIL THICKENING OR GELLING RHEOLOGICAL AGENT - The present invention relates to an anhydrous fluid composition comprising, in a cosmetically acceptable medium:
| 2011-08-18 |
20110200544 | UREA-BASED FILM-FORMING SOLUTION FOR TREATING NAIL PSORIASIS - The invention relates to a film-forming solution comprising: −10 to 20% of urea, −5 to 15% of film-forming polymer, 45 to 65% of a polar solvent, 1 to 20% of a co-solvent, 0.01 to 5% of a plasticizer selected from the list consisting of diethyl phthalate, triethyl citrate, dibutyl sebacate, diethyl sebacate, dibutyl phthalate, acetyltriethyl citrate, and polyethylene glycols, and water up to 100% intended for treating ungual fungic infections and nail psoriasis. | 2011-08-18 |
20110200545 | DEODORANT COMPOSITION AND METHODS FOR USE THEREOF - The invention comprises a deodorant composition for the treatment of fibers, hair, and/or skin. Preferred embodiments include compositions containing one or more of active ingredients L-arginine, acetylsalicyclic acid, and salicyclic acid adjusted to a pH in the range of 4.0 to 6.0. Preferred compositions include: a carrier, such as water; a moisturizer, such as propylene glycol; one or more of the active ingredients; along with optional preservatives, herbal extract, and skin protectants. Application of a composition for the treatment of odor forming microbes with a pH of about skin does not disrupt normal skin functioning. | 2011-08-18 |
20110200546 | PERFUMING INGREDIENTS OF THE FLORAL AND/OR ANIS TYPE - The present invention concerns a compound of formula wherein R represents a hydrogen atom or a C | 2011-08-18 |
20110200547 | COSMETIC COMPOSITION, COMPOUND AND COSMETIC TREATMENT METHOD - The invention relates to a cosmetic composition, particularly for hair care, and to a method for cosmetically treating keratin material, particularly the hair, using the compounds of Formula (I), where: —n=1, 2, 3, or 4; —R1, R′1, R2, and R′2 are H, —OH, —NRR′, or a C1-C18 carbon group capable of containing one or more heteroatoms selected from among O, S, and N; and —Z is a multivalent carbon radical optionally substitutable and/or interruptible by specific groupings, it being understood that said radical Z includes at least one heteroatom selected from among N, O, and S. | 2011-08-18 |
20110200548 | Aminofunctional Endblocked Silicone Polyether Copolymers In Personal Care Compositions - Personal care compositions containing aminofunctional endblocked silicone polyether copolymers are disclosed. The aminofunctional endblocked silicone polyether copolymers are particularly useful in hair care formulations to provide conditioning, which includes ease of detangling, combing, pliability, smoothness, slipperiness and styling benefits. | 2011-08-18 |
20110200549 | Organic Compounds Suitable For Modulating Fragrance Compositions - Disclosed are compounds having the ability to modulate, namely to improve, enhance and/or modify fragrance compositions due to their ability to inhibit cytochrome P450 enzymes, e.g. CYP2A, e.g. 2A13 and 2A6, and CYP2B6. | 2011-08-18 |
20110200550 | Multi-Arm Polymeric Alkanoate Conjugates - Among other aspects, provided herein are multi-armed polymer conjugates comprising an alkanoate-linker, compositions comprising such conjugates, and related methods of making and administering the same. Methods of treatment employing such conjugates and related uses are also provided. The conjugates are prepared with high drug loading efficiencies. | 2011-08-18 |
20110200551 | Mycoattractants and Mycopesticides - The present invention utilizes extracts of the pre-sporulation (preconidial) mycelial stage of entomopathogenic fungi as insect attractants and/or pathogens. The fungus can be cultivated on grain, wood, agricultural wastes or other cellulosic material. More than one fungus and substrate can be used in combination. | 2011-08-18 |
20110200552 | CYTOKINE DESIGN - The present invention relates to novel cytokines, which have a modified selectivity/specificity for their cognate receptors. In particular, the invention relates to a variant TRAIL protein, which has superior selectivity for the death receptor 4 (TRAIL-RI) over the death receptor 5 (TRAIL-R2). In addition, the invention relates to a variant TRAIL protein which exhibits superior selectivity for the death receptor 4 (TRAIL-R1) over the decoy receptors DcR1 (TRAIL-R3) and DcR2 (TRAIL-R4). | 2011-08-18 |
20110200553 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS - The present invention provides novel compounds represented by formula I: | 2011-08-18 |
20110200554 | THERAPEUTIC AGENT FOR HEPATITIS C - A novel therapeutic agent for hepatitis C having a high therapeutic effect against hepatitis C is disclosed. The therapeutic agent for hepatitis C contains as an effective ingredient hydroxyurea. The therapeutic agent for hepatitis C optionally further contains interferon α. By the present invention, a novel therapeutic agent for hepatitis C having a high therapeutic effect against hepatitis C was provided. A synergistic therapeutic effect against hepatitis C is obtained by using interferon α in combination. Therefore, in cases where a patient is infected with the genotype of hepatitis C virus for which therapy by interferon α is effective, the therapeutic effect is further promoted by using interferon α in combination. | 2011-08-18 |
20110200555 | CONJUGATES OF HYDROXYALKYL STARCH AND A PROTEIN - Conjugates of hydroxyalkyl starch and a protein are provided herein. The conjugates are formed by a convalent linkage between the hydroxyalkyl starch or a derivative of the hydroxyalkyl starch and the protein. Methods of producing the conjugates and the use of the conjugates also are provided herein. | 2011-08-18 |
20110200556 | CHEMOPREVENTION OF HEAD AND NECK SQUAMOUS CELL CARCINOMAS - Disclosed is a method for preventing the development of head and neck squamous cell carcinoma (HNSCC) in a mammal who is at risk for developing such carcinoma comprising administering an effective amount of a mammalian target of rapamycin (mTOR) inhibitor to the mammal. An example of such inhibitor is rapamycin. | 2011-08-18 |
20110200557 | NEW 2-AMIDOTHIADIAZOLE DERIVATIVES - The present disclosure relates to 2-amidothiadiazole derivatives of formula (I) as well as pharmaceutical compositions comprising them, and their use in therapy as agonists of the S1P1 receptors. | 2011-08-18 |
20110200558 | Treatment or Prevention of Hepatitis C with Immunomodulator Compounds - A method of treatment for treating or preventing hepatitis C (HepC) in a target subject, including administering to the target subject an effective amount of an immunomodulator compound of Formula A | 2011-08-18 |
20110200559 | METHOD FOR PRODUCTION OF THREE-DIMENSIONAL STRUCTURE OF CELLS - The present invention provides a method for arranging various cells as cell clusters in an arbitrary three-dimensional space and producing a three dimensional structure of a desired shape constituted exclusively by cells. Furthermore, the present invention provides a support provided with a substrate and a thread or needle-shaped material that penetrates the substrate and cell clusters for positioning cell clusters in arbitrary space. The support is provided with a sheet that can be removed as necessary for covering the substrate. Further, a method for using the support structure to position cell clusters in an arbitrary space and a method for the production of three-dimensional cell structures are provided. | 2011-08-18 |
20110200560 | NON-IONIC SELF-ASSEMBLING PEPTIDES AND USES THEREOF - The invention relates to a novel class of non-ionic, self-assembling peptides, compositions thereof, methods for the preparation thereof and methods of use thereof. | 2011-08-18 |
20110200561 | Method for Bacteriophage Delivery and Amplification - Disclosed are methods of selecting wide host range bacteriophage capable of growing in a plurality of bacteria including pathogenic and non-pathogenic bacteria and bacteriophage selected by the methods. Also disclosed are methods of treating a subject infected with a pathogenic bacterium using bacteriophage and methods of decontaminating objects using bacteriophage. Also disclosed are methods of producing vaccines. In another aspect, methods of determining bacterial viability and methods of improving the sensitivity of a biosensor using wide host range bacteriophages are disclosed. | 2011-08-18 |
20110200562 | Chimeric Cytokine of IL-7 and Beta Chain of HGF and Methods of Use - The present invention relates to a single-chain or chimeric polypeptide comprising a cytokine and a growth factor linked by at least one amino acid residue, and wherein the chimeric polypeptide enhances the proliferation and/or differentiation of hematopoietic precursor cells. In particular the invention relates to, a chimeric polypeptide comprising the beta-chain of hepatocyte growth factor, and IL-7 linked by at least one amino acid, and wherein the chimeric polypeptide demonstrates pre-pro-B proliferation and growth stimulating activity. | 2011-08-18 |
20110200563 | CALCIUM-MEDIATED EFFECTS OF CORAL AND METHODS OF USE THEREOF - This invention is directed to coral scaffolds seeded with precursor cells in culture in the presence of a chelator and uses thereof in inducing or enhancing bone and/or cartilage formation in a subject, and kits related thereto. This invention is also directed to use of cadherin-upregulating coral for treating cancer or inhibiting cancer progression. This invention is also directed to use of aragonite or calcite-producing species for in vivo calcium release, and its application to the treatment of skin diseases, disorders or conditions. | 2011-08-18 |
20110200564 | DIAGNOSIS AND TREATMENT OF ALZHEIMER'S DISEASE (AD) - Disclosed herein are novel methods, assays and systems for detecting an increased risk for Alzheimer's disease (AD) in a subject by identifying at least one nuclei acid polymorphism described herein in a biological sample from the subject. Levels of the genes associated with the nucleic acid polymorphism described herein are also determined for detection of higher risk for AD. Disclosed herein further provides methods for treating AD by administering to a subject in need thereof with ATXN1. | 2011-08-18 |
20110200565 | VIRUS CLEARANCE OF NEOPLASTIC CELLS FROM MIXED CELLULAR COMPOSITIONS - The present invention relates to a method for removing neoplastic cells from a mixed cellular composition, which is outside of a living organism, by using a virus which selectively infect and kill neoplastic cell. A variety of viruses can be used in this method to remove neoplastic cells for different purposes, for example, to purge hematopoietic stem cells prior to transplantation. Also provided are compositions prepared according to this method, and kits comprising a combination of viruses which are useful in this invention. | 2011-08-18 |
20110200566 | Compositions and Methods for the Treatment of Vitiligo - Compositions and methods for darkening skin and treating vitiligo are provided. | 2011-08-18 |
20110200567 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF LUNG DISEASES AND DISORDERS - A method of treating injured or diseased alveolar epithelial tissue in the lung of a mammal comprising transplanting into the lung a population of differentiated transgenic stem cells, or progeny thereof, which have an alveolar type II phenotype, effective to repair at least a portion of the injured or diseased alveolar epithelial tissue; an expression vector for transgenically modifying stem cells, comprising a DNA sequence encoding human surfactant protein C promoter operably linked to a DNA sequence encoding at least one drug-resistance gene; transgenic stem cells comprising such expression vector; and a method of preparing such transgenic stem cells and progeny thereof, a high percentage of which have an alveolar type II phenotype. | 2011-08-18 |
20110200568 | INDUCED PLURIPOTENT STEM CELLS - This document provides methods and materials related to induced pluripotent stem cells. For example, induced pluripotent stem cells, compositions containing induced pluripotent stem cells, methods for obtaining induced pluripotent stem cells, and methods for using induced pluripotent stem cells are provided. In addition, methods and materials for using induced pluripotent stem cells to repair tissue (e.g., cardiovascular tissue) in vivo as well as methods and materials for using induced pluripotent stem cells to assess their therapeutic potential in appropriate animal models are provided. | 2011-08-18 |
20110200569 | INCREASING THE SHELF LIFE OF BAKERY AND PATISSERIE PRODUCTS BY USING THE ANTIFUNGAL LACTOBACILLUS AMYLOVORUS DSM 19280 - The current inventions relates to a strain of | 2011-08-18 |
20110200570 | Composition and Method for Treating Infections and Promoting Intestinal Health - Compositions and methods for the treatment of intestinal infections. Compositions that include a liquid crystal mixture of an antimicrobial glycerol fatty acid ester and a polyhydric alcohol inhibit the growth of numerous deleterious intestinal pathogenic bacteria, including | 2011-08-18 |
20110200571 | Methods for Reducing Nematode Damage to Plants - Methods and compositions for controlling nematode plant damage using seed and/or soil and foliar treatments are disclosed. Seeds, soil, or both are treated with a nematicidal composition followed later by a foliar treatment by a different nematicidal composition. | 2011-08-18 |
20110200572 | Compositions for stabilizing bacillus spores and methods of use thereof - The invention provides methods for providing | 2011-08-18 |
20110200573 | Methods of inhibiting retrovirus replication and infectivity - The present invention provides methods of inhibiting a retrovirus replication or infectivity by administering a therapeutically effective amount of MOV10 or a fragment, derivative or analog thereof or an inhibitor of MOV10 or a fragment, derivative or analog thereof or of inhibiting a retrovirus replication or infectivity by increasing or decreasing transcription, translation or biological activity of MOV10 or a fragment, derivative or analog thereof. In some instances the retrovirus is HIV or HIV-1. The present invention also features methods of treating a disease caused all or in part by a retrovirus, such as HIV or HIV-1, by administering a therapeutically effective amount of MOV10 or a fragment, derivative or analog thereof or an inhibitor thereof or by increasing or decreasing transcription, translation or biological activity of MOV10 or a fragment, derivative or analog thereof. Further, the present invention features methods to identify an agent that may inhibit a retrovirus comprising identifying an agent that is regulated by MOV10 or a fragment, derivative or analog thereof. | 2011-08-18 |
20110200574 | USE OF PROTEASES FOR GLUTEN INTOLERANCE - The present technology relates to an enzyme composition. The enzyme composition may be used to treat gluten intolerant subjects, including suffering from non-Celiac gluten intolerance and/or non-Celiac gluten sensitivity. The enzyme composition may also be used to reduce gluten exposure in certain individuals. For example, the enzyme composition may also be used as a prophylactic to reduce exposure to gluten oligopeptides. | 2011-08-18 |
20110200575 | METALLO-LACTOFERRIN-COENZYME COMPOSITIONS TO IMPROVE SLEEP PATTERNS - Formulations are provided for the improvement of sleep patterns. The formulations generally include a trigger complex, an elemental complex and a coenzyme-vitamin B complex. The trigger complex is high in fiber such as glucomannan and includes Metallo-Lactoferrin protein in an alkaline buffer system. The elemental complex includes one or more trace element as a suitable salt. The coenzyme-vitamin B complex includes one or more coenzyme, coenzyme precursor and/or B-vitamin. The compositions may optionally include additional components such as 5-hydroxy-L-tryptophan (5-HTP), choline, melatonin, milk protein hydrolysate, L-arginine, and L-carnitine. The compositions can be administered orally in a variety of forms. | 2011-08-18 |
20110200576 | ENGINEERED ENZYMES WITH METHIONINE-GAMMA-LYASE ENZYMES AND PHARMACOLOGICAL PREPARATIONS THEREOF - Methods and composition related to the engineering of a novel protein with methionine-γ-lyase enzyme activity are described. For example, in certain aspects there may be disclosed a modified cystathionine-γ-lyase (CGL) comprising one or more amino acid substitutions and capable of degrading methionine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with methionine depletion using the disclosed proteins or nucleic acids. | 2011-08-18 |
20110200577 | BIOMATRICES TO ATTRACT AND RETAIN REGENERATIVE AND REPARATIVE CELLS - The invention relates to a pharmaceutical composition which comprises a fibrin clot and a cytokine and methods of delivering the composition to a site of disease or injury in vivo to attract and retain regenerative or reparative stem or myeloid cells and their differentiated progeny. | 2011-08-18 |
20110200578 | INTRAVENTRICULAR HEMORRHAGE THROMBOSIS - The invention provides methods of treating intraventricular hemorrhage using thrombolytic agents. | 2011-08-18 |
20110200579 | NOVEL GENE DISRUPTIONS, COMPOSITIONS AND METHODS RELATING THERETO - The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO57290 genes. Such in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or treatments useful in the prevention, amelioration or correction of diseases or dysfunctions associated with gene disruptions such as cardiovascular, endothelial or angiogenic disorders; immunological disorders; oncological disorders; bone metabolic abnormalities or disorders; or developmental abnormalities. | 2011-08-18 |
20110200580 | METHODS OF TREATMENT AND PREVENTION OF DIET-INDUCED OBESITY AND SEQUELAE THEREOF - Disclosed are methods of treating or preventing diet-induced obesity and/or one or more sequelae thereof in a subject. These methods comprise administering to a subject in need of treatment or at risk for developing diet-induced obesity and/or one or more sequelae thereof, a therapeutically effective amount of a pharmaceutical composition comprising at least one inhibitor of RP 105 and/or MD-I activity. Also disclosed are methods of identifying compounds that inhibit development of diet-induced obesity and/or one or more sequelae thereof. In some aspects, these methods comprise: providing at least one first cell comprising TLR4, MD-2. RP105. MD-K and a TLR4-responsive promoter operably linked to a nucleic acid sequence encoding a reporter, contacting the at least one first cell with lipopolysaccharide and with a candidate compound; and determining a level of expression of the reporter in the presence of the LPS and the candidate compound, in some aspects, these methods comprise: providing at least one first cell comprising TLR2, TLR1, TLR6, MD-2, RP H/S, MD-K and a TLR2-responsive promoter operably linked to a nucleic acid sequence encoding a reporter, contacting the at least one first cell with a lipopeptide ligand of TLR2 and with a candidate compound, and determining a level of expression of the reporter in the presence of the lipopeptide ligand of TLR2 and the candidate compound | 2011-08-18 |
20110200581 | PHARMACEUTICAL COMPOSITIONS - Synthesis natural tubulisine derivatives of formula (A) having a high cytotoxicity | 2011-08-18 |
20110200582 | LIPIDS, LIPID COMPOSITIONS, AND METHODS OF USING THEM - Disclosed are formulation and optimization protocols for delivery of therapeutically effective amounts of biologically active agents to liver, tumors, and/or other cells or tissues. Also provided are compositions and uses for cationic lipid compounds of formula (I). | 2011-08-18 |
20110200583 | Asthma Susceptibility Loci Located at Chromosome 1q31 for Use in Diagnostic and Therapeutic Methods - Methods and composition are provided for diagnosing pediatπc onset asthma based on the single nucleotide polymorphism on chromosome 1q31 wherein said single nucleotide polymorphism is set forth in Table 2 or Table 6 of the instant invention Method and composition are also provided for treating and preventing asthma or other inflammatory conditions in a patient in need thereof compπsing administering an effective amount of an at least one inhibitor which reduces the expression of DENND1 B gene product. | 2011-08-18 |
20110200584 | METHOD TO STIMULATE IMMUNE FUNCTION AND REGENERATION - The present relates to a method to stimulate thymocytes to differentiate, proliferate and increase thymic output by administration of a hormone-based reagent. | 2011-08-18 |
20110200585 | CD127 BINDING PROTEINS - Antigen binding proteins which bind to human IL-7 receptor (CD127) are provided. The antigen binding proteins are typically antibodies, and are useful in the treatment of diseases or disorders in humans, particularly autoimmune diseases such as multiple sclerosis. | 2011-08-18 |
20110200586 | AMINOTHIAZOLONES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS - The present invention relates to compounds of Formula (I), | 2011-08-18 |
20110200587 | AMINOTHIAZOLONES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS - The present invention relates to compounds of Formula (I), | 2011-08-18 |
20110200588 | METHODS FOR GENETIC ANALYSIS - Methods of treating an individual exhibiting a medical condition are disclosed. The methods involve determining a score of an individual based on the individual's genotypic information, comparing the score to at least one threshold value, wherein the result of the comparison is indicative of a beneficial response to a treatment, and providing a suitable treatment to the individual. | 2011-08-18 |
20110200589 | DECONVOLUTION METHOD - The present invention relates generally to novel applications in combating infectious disease, cancer, allergy and autoimmune diseases. In one aspect, the invention relates to identifying one or more protein binding moieties of interest. In another aspect, the present invention relates to identifying one or more candidate vaccines. | 2011-08-18 |
20110200590 | Antibodies Directed Against the Myelin Basic Protein Recognising an Epitope of CD64 and Their Use as Immunosuppressants - It is described an antibody, recombinant or synthetic fragments thereof able to recognise and bind at least one epitope of the myelin basic protein. The antibody is also able to recognise also an epitope of the protein of the class of Fc receptors (FcR), namely CD64. Therapeutic applications are also disclosed. | 2011-08-18 |
20110200591 | PRODUCTS AND METHODS TO PREVENT INFECTIONS - The present invention relates to products and methods for preventing, ameliorating and/or treating infections and other diseases. In one aspect, the products of the present invention relates to compositions comprising germ free colostrum. In another aspect, the products of the present invention relates to compositions comprising synthetically multimerised immunoglobulins. In a third aspect, the products of the present invention relates to compositions comprising germ free colostrum enriched with synthetically multimerised immunoglobulins. The invention also relates to use of said compositions as a pharmaceutical e.g. for prophylactic or ameliorating treatment of infections and other diseases. In addition the invention comprises methods for production of said compositions. | 2011-08-18 |
20110200592 | Methods For Reducing Viral Load in HIV-1 Infected Patients - This method provides a method for reducing HIV-1 viral load in an HIV-1-infected human subject which comprises administering to the subject at a predefined interval effective HIV-1 viral load-reducing doses of (a) a humanized antibody designated PRO 140, or of (b) an anti-CCR5 receptor monoclonal antibody. This invention also provides a method for inhibiting in a human subject the onset or progression of an HIV-1-associated disorder, the inhibition of which is effected by inhibiting fusion of HIV-1 to CCR5 | 2011-08-18 |
20110200593 | Combination Therapy for the Treatment of Ocular Neovascular Disorders - The invention features methods for treating a patient diagnosed with, or at risk of developing, a neovascular disorder by administering a PDGF antagonist and a VEGF antagonist to the patient. The invention also features a pharmaceutical composition containing a PDGF antagonist and a VEGF antagonist for the treatment or prevention of a neovascular disorder. | 2011-08-18 |
20110200594 | FUNCTIONALIZED POLYPEPTIDES - The invention provides functionalized polypeptides, especially therapeutic polypeptides (e.g., scFv), comprising a linker sequence that can be rapidly and specifically functionalized by the addition of one or functional moieties (e.g., PEG) or binding specificities (e.g., an amino acid sequence with a particular binding specificity). Such functionalized polypeptides are advantageous in that they have improved pharmacokinetic properties (e.g., improved in vivo half-life, tissue penetration and tissue residency time) over non-functionalized polypeptides. Methods for the rapid and reproducible generation of functionalized polypeptides are also provided. | 2011-08-18 |
20110200595 | TREATMENT WITH A HUMANIZED IgG CLASS ANTI EGFR ANTIBODY AND AN ANTIBODY AGAINST INSULIN LIKE GROWTH FACTOR 1 RECEPTOR - The present invention provides a humanized IgG-class anti-EGFR antibody and an anti-IGF-1R antibody for combined use in treating cancer, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy. The invention also encompasses a pharmaceutical composition that is comprised of a combination of a humanized IgG-class anti-EGFR antibody and an anti-IGF-1R antibody in a pharmaceutically acceptable carrier. | 2011-08-18 |
20110200596 | MONOVALENT ANTIBODY FRAGMENTS USEFUL AS THERAPEUTICS - The invention provides methods and compositions comprising a novel stabilized monovalent antibody fragment. | 2011-08-18 |
20110200597 | SIGNAL PATHWAY ALTERATIONS AND DRUG TARGET ELEVATIONS IN PRIMARY METACHRONOUS METASTATIC COLORECTAL CANCER COMPARED TO NON-METASTATIC DISEASE - The present invention relates to the identification and diagnostic use of biomarkers in primary colorectal cancer tumors whose activation level are predictive of the likelihood of the onset of metastatic disease. These biomarkers may be used to determine the suitability of a patient for aggressive and/or targeted treatments. Kits and compositions of the invention are also provided. | 2011-08-18 |
20110200598 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A PROTEASOME INHIBITOR - The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a proteasome inhibitor for the treatment of a patient suffering from cancer, particularly a CD20-expressing cancer. An aspect of the invention is a composition comprising a type II anti-CD20 antibody and a proteasome inhibitor. Another aspect of the invention is a kit comprising a type II anti-CD20 antibody and a proteasome inhibitor. Yet another aspect of the invention is a method for the treatment of a patient suffering from cancer comprising co-administering, to a patient in need of such treatment, a type II anti-CD20 antibody and a proteasome inhibitor. | 2011-08-18 |
20110200599 | SUSTAINED DRUG DELIVERY SYSTEM - A drug composition comprising a charged moiety coupled to a therapeutic compound is disclosed. The charged moiety is configured to interact with at least one type of component of opposite charge in a biological tissue to create an in situ depot for prolonged drug delivery. The biological tissue may be eye tissue or any tissue containing charged components. Further, a method of treating the human body is disclosed. The method is for introducing into a human body a drug composition comprising a charged moiety coupled to a therapeutic compound. Introduction may be through injection. A method of manufacturing a drug composition comprising a charged moiety coupled to a therapeutic compound is also disclosed. | 2011-08-18 |
20110200600 | DIAGNOSIS AND PROGNOSIS OF IMMUNE DISORDERS USING STAT4 EXPRESSION - Methods and compositions that determine the expression levels of Stat4α and Stat4β isoforms for therapeutic efficacy of anti-inflammatory treatments, assessing an individual's risk for developing inflammatory diseases including Crohn's disease, ulcerative colitis, rheumatoid arthritis, and multiple sclerosis are disclosed. | 2011-08-18 |
20110200601 | Drug Delivery to Human Tissues by Single Chain Variable Region Antibody Fragments Cloned by Phage Display - The present invention relates to the use of non-pathogenic antibodies to deliver biologically-active proteins to specific cellular and sub-cellular sites. The invention also relates to the use of non-pathogenic antibodies to deliver biologically-active, non-protein molecules to specific cellular and sub-cellular sites. | 2011-08-18 |
20110200602 | ANTIBODIES TO EGFL7 AND METHODS FOR THEIR USE - The invention provides anti-EGFL7 antibodies, and compositions comprising and methods of using these antibodies. | 2011-08-18 |
20110200603 | NEW ANTIGENS FOR PARATUBERCULOSIS DIAGNOSIS AND VACCINATION - Antigens of | 2011-08-18 |
20110200604 | IDENTIFICATION OF NOVEL IgE EPITOPES - The present invention relates to novel peptide epitopes derived from the CH3 domain of IgE which are recognized by high affinity antibodies that specifically bind IgE. These novel peptides may be used for both active immunization of a subject by administering these peptides to generate high affinity antibodies in a subject, as well as for generating high affinity anti-IgE antibodies in non-human hosts that specifically bind to these regions of IgE for passive immunization of a subject. | 2011-08-18 |
20110200605 | Polypeptides and use thereof - An isolated polypeptide comprises an amino acid sequence of SEQ ID No. 1 or 2 or a variant or fragment thereof. The variant may comprise an amino acid sequence that is at least 70% or 95% identical to the amino acid sequence of SEQ ID No. 1 or 2. A fragment thereof may be a peptide comprising at least 12 contiguous amino acids of SEQ ID No. 1 or 2. The polypeptide exhibits toll-like receptor activity. The TLR has been named TLR1 4. TLR receptors recognise a range of ligands and activate a series of signalling pathways that lead to the induction of immune and inflammatory genes. | 2011-08-18 |
20110200606 | Antibodies that Bind to Lysyl Oxidase-Like 2 (LOXL2) and Methods of Use Therefor - The present disclosure provides lysyl oxidase-like-2 (LOXL2) polypeptide binding agents, including, for example, antibodies that specifically bind a LOXL2 polypeptide; and further provides compositions comprising same. The binding agents can be used in various treatment and diagnostic methods, which are also provided. | 2011-08-18 |
20110200607 | Binding Proteins Specific for Insulin-Like Growth Factors and uses Thereof - Binding proteins, such as antibodies directed to IGF-II with cross-reactivity to IGF-I and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the IGF-II with cross-reactivity to IGF-I are disclosed. Also discussed are nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3. | 2011-08-18 |
20110200608 | FULLY HUMAN ANTIBODIES TO HIGH MOLECULAR WEIGHT-MELANOMA ASSOCIATED ANTIGEN AND USES THEREOF - Disclosed herein are isolated human monoclonal antibodies, and functional fragments thereof, that specifically bind HMW-MAA. Nucleic acids encoding these antibodies, expression vectors including these nucleic acid molecules, and isolated host cells that express the nucleic acid molecules are also disclosed. The antibodies can be used to detect HMW-MAA in a sample. Methods of diagnosing cancer, or confirming a diagnosis of cancer, are disclosed herein that utilize these antibodies. Methods of treating a subject with cancer are also disclosed. | 2011-08-18 |
20110200609 | MONOCLONAL ANTIBODIES SPECIFIC FOR PATHOLOGICAL AMYLOID AGGREGATES COMMON TO AMYLOIDS FORMED FROM PROTEINS OF DIFFERING SEQUENCE - Monoclonal antibody compositions, methods of production and use. The monoclonal antibodies are specific to conformational epitope(s) of a prefibrillar aggregate(s) which contribute to amyloid fibril formation in human or animal subjects who suffer from amyloid diseases (e.g., Alzheimer's Disease) and the hybridomas and monoclonal antibodies produced therefrom. The monoclonal antibodies are useable for immunization of human or animal subjects against Alzheimer's Disease or other amyloid diseases and/or for the diagnosis or detection of Alzheimer's Disease or other amyloid diseases. The monoclonal antibodies may be administered concomitantly or in combination with anti-inflammatory agents, such as gold or gold containing compounds, to decrease neural inflammation associated with amyloid diseases (e.g., Alzheimer's Disease). | 2011-08-18 |
20110200610 | Immuno-Modulating Compositions for the Treatment of Immune-Mediated Disorders - The present invention relates to immunomodulatory compositions comprising mammalian colostrum-derived immunoglobulin preparation and optionally further colostrums, milk or milk product component/s and any adjuvants for treating immune-related disorders. More specifically, the invention provides compositions comprising colostrum-derived anti-insulin immunoglobulin preparations for the treatment of Metabolic Syndrome. The invention further provides methods and uses of the immunomodulatory compositions for an active or passive immunization in a disease-antigen specific or non specific manner. | 2011-08-18 |
20110200611 | PLASMA KALLIKREIN BINDING PROTEINS - Plasma kallikrein binding proteins and methods of using such proteins are described. | 2011-08-18 |
20110200612 | TREATMENT OF EYE DISEASES AND EXCESSIVE NEOVASCULARIZATION USING COMBINED THERAPY - The present invention relates to methods of treating or preventing eye diseases, as well as angiogenesis-related diseases, by combination therapy involving administration of cells and a compound that disrupts VEGF-signalling. | 2011-08-18 |
20110200613 | Use of B Cell Expansion Agents in Generating Antibodies - A method for efficiently generating antibodies immunizes an animal with a target antigen and a B cell expansion agent, such as an anti-CD40 agonist. The antibodies generated from this method are useful as therapeutic agents, diagnostic agents or research reagents in a variety of diseases and conditions. | 2011-08-18 |
20110200614 | ANTHRAX SPECIFIC ANTIBODIES - The present invention is directed to diagnostic tools and therapies using antibodies to | 2011-08-18 |
20110200615 | Antibodies that Neutralize Botulinum Neurotoxins - This disclosure provides antibodies that specifically bind to and typically neutralize botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/E, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism. | 2011-08-18 |
20110200616 | Immunizing Compositions and Methods of Use - The present invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of making and methods of using such compositions. | 2011-08-18 |
20110200617 | COMBINATION THERAPY OF BETA-GLYCOLIPIDS AND ANTIBODIES FOR THE TREATMENT OF IMMUNE-RELATED DISORDERS - The present invention relates to a combination therapy for the treatment of immune-related disorders. More particularly, the invention relates to oral or mucosal synergistic compositions combining beta-glycolipids, preferably, β-glycosphingolipids with immunoglobulin molecules specific for at least one antigen derived from a component of the immune system, specifically an anti-CD3 antibody. The invention further provides methods kits and uses of the combined compositions of the invention for immuno-modulation and thereby for the treatment of immune-related disorders. In a preferred embodiment, anti-CD3 anti-body (OKT3) is orally administered in combination with β-glucosylceramide (also known as glycocerebroside) in an animal model of type 2 diabetes. | 2011-08-18 |
20110200618 | ERBB4 INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROPSYCHIATRIC DISORDERS - This invention relates to treatment of neuro-psychiatricdisorders. Specifically, the invention relates to the use of small molecule agent specific against erbB4, erbB3 or their combination, or fragments thereof in inhibiting the attachment of erbB4, erbB3 or their combination to NRG1. | 2011-08-18 |
20110200619 | PHARMACEUTICAL COMPOUNDS AS CYTOTOXIC AGENTS AND USES THEREOF - Disclosed are compounds effective as cytotoxic agents. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs. | 2011-08-18 |
20110200620 | B7-H1 AND METHODS OF DIAGNOSIS, PROGNOSIS, AND TREATMENT OF CANCER - The invention features methods of diagnosis by assessing B7-H1 expression in a tissue from a subject that has, or is suspected of having, cancer, methods of treatment with agents that interfere with B7-H1-receptor interaction, methods of selecting candidate subjects likely to benefit from cancer immunotherapy, and methods of inhibiting expression of B7-H1. | 2011-08-18 |
20110200621 | COMPOSITIONS AND METHODS FOR TREATING CANCER - This invention generally relates to compositions and methods for targeted delivery of chemotherapeutic agents to cancerous and pre-cancerous cells, thereby treating a cancer in a subject. | 2011-08-18 |
20110200622 | POLYPEPTIDE SPECIFICALLY BINDING TO VASCULAR ENDOTHELIAL GROWTH FACTOR, FUSION PROTEIN INCLUDING POLYPEPTIDE, AND METHODS THEREFOR - A polypeptide inhibiting binding between a vascular endothelial growth factor and a vascular endothelial growth factor receptor, a fusion protein including the same, and a method of preparing the fusion protein are disclosed. | 2011-08-18 |
20110200623 | POLYPEPTIDE COMPLEX COMPRISING NON-PEPTIDYL POLYMER HAVING THREE FUNCTIONAL ENDS - Disclosed is a protein complex, comprising a physiologically active polypeptide, a dimeric protein and a non-peptidyl polymer having three functional ends (3-arm), with the linkage of both the physiologically active polypeptide and the dimeric protein to the 3-arm non-peptidyl polymer via respective covalent bonds. The protein complex guarantees the long acting activity and biostability of a physiologically active polypeptide. Having the ability to maintain the bioactivity of physiologically active polypeptides or peptides highly and to significantly improve the serum half life of the polypeptides or peptides, the protein complex can be applied to the development of sustained release formulations of various physiologically active polypeptide drugs. Also, it utilizes raw materials including the physiologically active polypeptides without significant loss, thereby increasing the production yield. Further, it can be easily purified. | 2011-08-18 |
20110200624 | NOVEL PEPTIDES FOR USE IN TRANSFECTION - Novel peptides derived from antibody complementarity determining regions (CDRs) that enhance delivery of macromolecules into cells, particularly when used in combination with cationic lipids, are provided. The peptides can be combined with cationic lipids, and compositions of cationic lipids associated with enhancer elements, to provide reagents that can complex with macromolecules such as nucleic acids, proteins and peptides and permit introduction of these macromolecules into a variety of cells and tissues in vitro or in vivo with greatly enhanced efficiency compared to other lipid-based reagents. Methods for delivering macromolecules into target cells and tissues using the lipids and enhancer elements are provided. | 2011-08-18 |
20110200625 | PHARMACEUTICAL COMPOSITION - A nonirritant, thickened pharmaceutical composition comprising a drug which is normally solid and which has anti-angiogenesis properties and/or immunosuppressant properties, a normally solid dermal penetration-facilitator for the drug, a solvent which is capable of dissolving the drug and the facilitator; and a thickening agent. | 2011-08-18 |
20110200626 | IQGAP3 EPITOPE PEPTIDES AND VACCINES CONTAINING THE SAME - Peptide vaccines against cancer are described herein. In particular, the present invention describes epitope peptides derived from IQGAP3 that elicit CTLs. The present invention also provides established CTLs that specifically recognize HLA-A24 or HLA-A02 positive target cells pulsed with the peptides. Antigen-presenting cells and exosomes that present any of the peptides, as well as methods for inducing antigen-presenting cells are also provided. The present invention further provides pharmaceutical agents containing the IQGAP3 polypeptides or polynucleotides encoding thereof, as well as exosomes and antigen-presenting cells as active ingredients. Furthermore, the present invention provides methods for treating and/or prophylaxis of (i.e., preventing) cancers (tumors), and/or prevention of postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the IQGAP3 polypeptides, polynucleotides encoding the polypeptides, exosomes or antigen-presenting cells presenting the polypeptides, or the pharmaceutical agents of the present invention. The cancers to be targeted include, but are not limited to, renal, esophageal, gastric, lung, breast, bladder and pancreatic cancer. | 2011-08-18 |
20110200627 | ANTI-CD147 ANTIBODIES, METHODS AND USES - The present invention provides antibodies immunospecific for human CD 147 capable of blocking bioactivity of CD 147 associated with malignant disease such as the stimulation of MMPs from fibroblast cells by tumor cells, the release of VEGF, and the promotion of angiogenesis. The antibodies of the present invention of are useful in treating malignant disease and those diseases in which CD 147 activity is plays a pathogenic role, such as diseases of the eye, lung, and cardiovascular system. | 2011-08-18 |
20110200628 | Chimeric Proteins that Induce Effects Directed Against Viruses - The present invention is related to the obtaining of chimeric chains coding for proteins capable of inducing, in the recipient, a serotype-specific and protective humoral immune response against the infection by the Dengue virus, thus eliminating the effects of the serotype-nonespecific viral immunoenhancement that causes hemorrhagies and clinical complications described for this kind of pathology. These chimeric chains of nucleic acids are composed by the specific combination of fragments belonging to the gene of a mutated protein from | 2011-08-18 |
20110200629 | TUMOR ANTIGEN PEPTIDE AND USE THEREOF - Disclosed is a peptide consisting of the identical amino acid sequence or a substantially identical amino acid sequence to the amino acid sequence depicted in SEQ ID NO:4, wherein the peptide binds to an HLA antigen and is recognized by cytotoxic T cells. The peptide of the present invention can be used in vivo or in vitro as an agent for inducing CTL, that is, cancer vaccine, and exerts therapeutic or ameliorating effects on tumors such as osteosarcoma, renal cancer, and others. The peptide of the present invention is also useful as a tumor marker directed to tumors such as sarcoma, renal cancer, and others. | 2011-08-18 |
20110200630 | LIVE ATTENUATED VIRUS VACCINES FOR LA CROSSE VIRUS AND OTHER BUNYAVIRIDAE - The invention relates to vaccine compositions including CEV serogroup immunogens, attenuated and inactivated viruses of the CEV serogroup and chimeric Bunyaviridae. Also disclosed are methods of treating or preventing CEV serogroup infection in a mammalian host, methods of producing a subunit vaccine composition or an immunogenic composition, isolated polynucleotides comprising a nucleotide sequence encoding a CEV serogroup immunogen, methods for detecting La Crosse virus (LACV) infection in a biological sample and infectious chimeric Bunyaviridae. | 2011-08-18 |